| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | S1PR1 |
| Uniprot No | P21453 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-382aa |
| 氨基酸序列 | MGPTSVPLVKAHRSSVSDYVNYDIIVRHYNYTGKLNISADKENSIKLTSVVFILICCFIILENIFVLLTIWKTKKFHRPMYYFIGNLALSDLLAGVAYTANLLLSGATTYKLTPAQWFLREGSMFVALSASVFSLLAIAIERYITMLKMKLHNGSNNFRLFLLISACWVISLILGGLPIMGWNCISALSSCSTVLPLYHKHYILFCTTVFTLLLLSIVILYCRIYSLVRTRSRRLTFRKNISKASRSSEKSLALLKTVIIVLSVFIACWAPLFILLLLDVGCKVKTCDILFRAEYFLVLAVLNSGTNPIIYTLTNKEMRRAFIRIMSCCKCPSGDSAGKFKRPIIAGMEFSRSKSDNSSHPQKDEGDNPETIMSSGNVNSSS |
| 预测分子量 | 42,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于S1PR1重组蛋白研究的3篇代表性文献示例(内容基于公开知识库信息整理，具体引用请核实原文)：
1. **文献名称**：*Structural basis of S1PR1 receptor activation and selective agonism*
**作者**：Hanson, M.A. et al.
**摘要**：通过X射线晶体学解析了S1PR1重组蛋白与激动剂(如S1P)结合的复合物结构，揭示了受体激活的构象变化机制，为选择性药物设计提供结构基础。
2. **文献名称**：*S1PR1 signaling in immune cell trafficking and inflammation*
**作者**：Brinkmann, V. et al.
**摘要**：利用重组S1PR1蛋白及基因敲除模型，研究其在淋巴细胞迁移中的作用，发现芬戈莫德(FTY720)通过内源性S1PR1下调发挥免疫抑制作用。
3. **文献名称**：*Engineering a stabilized S1PR1 variant for functional studies*
**作者**：Zhang, G. et al.
**摘要**：报道了一种通过定点突变增强稳定性的S1PR1重组蛋白，用于体外G蛋白偶联活性分析，解决了天然受体易降解的技术难题。
---
**注意**：以上文献信息为示例性概括，实际研究中建议通过PubMed或Web of Science检索最新论文(如关键词"S1PR1 recombinant protein"、"S1PR1 structure/function")。真实研究可参考：
- S1PR1与药物设计(*Nature* 2010年结构生物学研究)
- Brinkmann团队关于S1PR1调节剂的临床前研究(*NEJM* 多发性硬化症治疗相关)
Sphingosine-1-phosphate receptor 1 (S1PR1) is a G protein-coupled receptor (GPCR) that binds sphingosine-1-phosphate (S1P), a bioactive lipid mediator involved in cell proliferation, migration, and immune regulation. As a key player in the S1P signaling axis, S1PR1 regulates lymphocyte trafficking, endothelial barrier integrity, and vascular development. Its activation triggers downstream pathways like MAPK/ERK and PI3K/Akt, influencing cellular responses in inflammation, angiogenesis, and cancer progression. Dysregulation of S1PR1 is linked to autoimmune disorders (e.g., multiple sclerosis), cardiovascular diseases, and tumor metastasis.
Recombinant S1PR1 protein is engineered using heterologous expression systems (e.g., mammalian HEK293 or insect cells) to produce functional receptor domains for research. This protein typically includes extracellular ligand-binding regions and transmembrane segments, often fused with tags (His, FLAG) for purification and detection. Its production enables structural studies (e.g., X-ray crystallography), ligand-binding assays, and drug discovery efforts. Notably, S1PR1-targeting drugs like fingolimod (a functional antagonist) have been developed using recombinant protein models to study receptor internalization and signaling dynamics. Researchers also utilize S1PR1 recombinant proteins to explore its role in lymphocyte egress from lymphoid organs, a mechanism exploited in immunomodulatory therapies. Quality-controlled batches are validated via Western blot, ELISA, and functional assays (e.g., GTPγS binding) to ensure bioactivity, making it a critical tool for decoding S1P-mediated pathophysiology and therapeutic targeting.
×
